Arfolitixorin
PreclinicalSmall molecule
Arfolitixorin is one of 4 small molecule programs targeting Metastatic Colorectal Cancer (mCRC). It is currently in Preclinical.
1
Indications
3
Total Trials
1
Active Trials
3
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
3 competitors in Metastatic Colorectal Cancer (mcrc)
#DrugCompanyPhaseTrials
1Fudr
PfizerPhase 2
Decadron
AAspen Global Incorporated
Phase 2
PDS01ADC
NNational Cancer Institute (NCI)
Phase 2
Arfolitixorin
IIsofol Medical AB
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Liver Metastases1 trial
Colorectal Cancer1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Arfolitixorin. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Preclinical[1]
- Company
- IIsofol Medical AB